Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis

• Published in: Circulation research Vol. 124; no. 3; pp. 437 - 450
• Main Author: Ridker, Paul M
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 01-02-2019
• Subjects: Animals; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Atherosclerosis - complications; Atherosclerosis - drug therapy; C-Reactive Protein - antagonists & inhibitors; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - prevention & control; CD40 Antigens - antagonists & inhibitors; CD40 Ligand - antagonists & inhibitors; Diabetes Mellitus, Type 2 - complications; Disease Models, Animal; Hematopoiesis; Humans; Inflammasomes - antagonists & inhibitors; Interleukin-18 - antagonists & inhibitors; Interleukin-1beta - antagonists & inhibitors; Interleukin-6 - antagonists & inhibitors; Methotrexate - therapeutic use; Mice; NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic - complications; Signal Transduction - drug effects; Stroke - prevention & control; Thrombosis - drug therapy; Thrombosis - etiology; Triggering Receptor Expressed on Myeloid Cells-1 - antagonists & inhibitors; cytokines; cardiovascular diseases; inflammasomes; humans; interleukins
• ISSN: 0009-7330; 1524-4571; 1524-4571
• DOI: 10.1161/CIRCRESAHA.118.313129

The recognition that atherosclerosis is a complex chronic inflammatory disorder mediated through both adaptive and innate immunity has led to the hypothesis that anticytokine therapies targeting specific IL (interleukin) signaling pathways could serve as powerful adjuncts to lipid lowering in the prevention and treatment of cardiovascular disease. Cytokines involved in human atherosclerosis can be broadly classified as proinflammatory and proatherogenic (such as IL-1, IL-6, and TNF [tumor necrosis factor]) or as anti-inflammatory and antiatherogenic (such as IL-10 and IL-1rA). The recent CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) has shown that specific targeting of IL-1β can significantly reduce cardiovascular event rates without lipid or blood pressure lowering. In CANTOS, the magnitude of benefit of this cytokine-targeted approach to atherosclerosis treatment was associated to the magnitude of reduction of the central signaling cytokine IL-6 and the downstream clinical biomarker high-sensitivity CRP (C-reactive protein). By contrast, in the recent CIRT (Cardiovascular Inflammation Reduction Trial), low-dose methotrexate neither reduced IL-1β, IL-6, or high-sensitivity CRP nor lowered cardiovascular event rates. Taken together, these 2 contemporary trials provide proof of principle that focused cytokine inhibition, not broad-spectrum anti-inflammatory therapy, is likely to be crucial for atheroprotection. This review provides an overview of cytokines in atherosclerosis, the potential benefits and risks associated with targeted anticytokine therapies, and a look to the future of clinical practices addressing residual inflammatory risk.